App-Quantinova.ai

SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, PROVIDES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): 2 YEAR FOLLOW-UP FROM THE CARDINAL STUDY

Alexander Rth - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

PHARMACEUTICAL TARGETING OF RAS IN ACUTE MYELOID LEUKAEMIA

Daniel Coleman - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

CPX-351 TREATMENT FOR ACUTE MYELOID LEUKEMIA IN ENGLAND: REAL-WORLD OUTCOMES IN ADULTS AGED <60 YEARS VERSUS ≥60 YEARS

Alex Legg - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

daunorubicin + cytarabine

DUAL EPIGENETIC AND GENETIC EDITING OF PRIMARY HUMAN HAEMATOPOIETIC STEM AND PROGENITOR CELLS

Emily Saunderson - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

PREDICTING THE RESPONSE OF DLBCL CELLS TO BH3-MIMETICS USING SYSTEMS BIOLOGY

Ielyaas Cloete - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Venetoclax

MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Rafael Fonseca - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: 6-YEAR FOLLOW-UP AND GENOMIC ANALYSES IN A PIVOTAL PHASE 2 TRIAL

Stephan Stilgenbauer - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Venetoclax

LOCKDOWNS AND CANCER DIAGNOSIS: IMPACT OF COVID19 PANDEMIC ON NEW HAEM-ONC PRESENTATIONS

David Discalicau - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA

Jens Hillengass - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Cytokine release syndrome

Lenalidomide

A MULTICENTER, INTERNATIONAL COLLABORATIVE STUDY EVALUATING FRONTLINE THERAPY WITH BENDAMUSTINE RITUXIMAB FOR WALDENSTRÖM MACROGLOBULINEMIA

Saurabh Zanwar - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Bendamustine

FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA

Umberto Vitolo - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Lenalidomide

TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PFS CO-PRIMARY ENDPOINT OF THE RANDOMIZED PHASE 3 GAIA/CLL13 TRIAL

Barbara Eichhorst - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Obinutuzumab

LOSS OF NR4A1 IS ASSOCIATED WITH HIGHER EXPRESSION OF IMMUNE CHECKPOINT COMPONENTS AND REDUCED T CELL-MEDIATED LYMPHOMA CELL KILLING IN AGGRESSIVE LYMPHOMA

Katrin Pansy - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

FLOW CYTOMETRY COMBINED WITH SYSTEMS BIOLOGY ENABLES RATIONAL TARGETING OF NFKB IN DLBCL

Eleanor Jayawant - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

AN AUDIT OF PAIN EDUCATION IN PATIENTS WITH SICKLE CELL DISEASE

Yuhui Zhou - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS

Austin Kulasekararaj - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

N/A

NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY

Vinod Pullarkat - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thrombocytopenia

Navitoclax

EFFECT OF TYROSINE KINASE INHIBITORS ON MALE FERTILITY IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA

George Nesr - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

L-Tyrosine

4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION

David C. Dale - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

AMD-070

STATUS OF IRREGULAR ANTIBODIES IN THE COVID ERA: A NEW PRESSURE FOR THE TRANSFUSION DEPARTMENT?

Harberth Fernandez Leyva - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Filters

45280 Abstracts